A practical reference on LC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-31. Anything still debated is marked as such rather than presented as settled.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
=== Longevity === Giant tortoises are among the longest-lived vertebrate animals (over 100 years by some estimates) and have been used as a model for studying longevity. DNA analysis of the genomes of Lonesome George, the iconic last member of Chelonoidis abingdonii, and the Aldabra giant tortoise Aldabrachelys gigantea led to the detection of lineage-specific variants affecting DNA repair genes that might contribute to our understanding of increased lifespan.
==== Chromatographic methods ==== A variety of chromatographic methods can be used to analyse YTXs. This includes chromatographic techniques coupled to mass spectrometry and fluorescence detectors. All of the chromatographic techniques require a calibration step prior to sample analysis.
== SJ == SJ (s) Svalbard and Jan Mayen (ISO 3166 digram) (i) Societas Iesu (Latin: The Society of Jesus, the Jesuit order) (i) Statens Järnvägar (Swedish State Railways) SJA – (i) Staff Judge Advocate (military law) SJC – (i) Supreme Judicial Court of Massachusetts (note: the highest court in the state of Maine is also called the Supreme Judicial Court) SJM – (s) Svalbard and Jan Mayen (ISO 3166 trigram) SJW – (i) Social Justice Warrior
Sources: en.wikipedia.org
In his introduction to the 1895 edition of Karl Marx's The Class Struggles in France, Engels attempted to resolve the division between gradualist reformist and revolutionary socialists in the Marxist movement by declaring that he was in favour of short-term tactics of electoral politics that included gradualist and evolutionary socialist policies while maintaining his belief that revolutionary seizure of power by the proletariat should remain a key goal of the socialist movement. In spite of this attempt by Engels to merge gradualism and revolution, his effort only diluted the distinction of gradualism and revolution and had the effect of strengthening the position of the revisionists. Engels' statements in the French newspaper Le Figaro in which he argued that "revolution" and the "so-called socialist society" were not fixed concepts, but rather constantly changing social phenomena and said that this made "us [socialists] all evolutionists", increased the public perception that Engels was gravitating towards evolutionary socialism. Engels also wrote that it would be "suicidal" to talk about a revolutionary seizure of power at a time when the historical circumstances favoured a parliamentary road to power which he predicted could happen "as early as 1898." Engels' stance of openly accepting gradualist, evolutionary and parliamentary tactics while claiming that the historical circumstances did not favour revolution caused confusion among political commentators and the public.
== Career == Aramwit's career started as a Formulator/Research Investigator at Pfizer Pharmaceutical Worldwide in the USA. She then served as the deputy director for International Affairs and Immigrant Workers at the Internal Security Operations Command in Thailand from April 2014 to 2017. Since then, she has been serving as the Acting Vice President on the President and Administrative Board, while concurrently holding the position of Director of Research Projects at Center of Excellence in Bioactive Resources for Innovative Clinical Applications (BRICA) and Dean of the Faculty of Pharmaceutical Sciences at the Department of Pharmacy Practice (PharmCU) at CU. Within these roles, she oversaw collaborations on nutritional supplements with Innobic (Asia) and TISTR, led skincare product development with CU Innovation Hub and UMI Deeptech, and contributed to StemAktiv's research, highlighting its potential in skincare and aging treatment with safe herbal extracts, while also overseeing CU's Faculty of Pharmaceutical Sciences signing an MOU with Mahidol University and another MOU with Degree Plus. In addition, she has been appointed as an adjunct professor in the Faculty of Pharmacy at the Silpakorn University in Thailand and a visiting professor at the Institute of Natural Medicine of the University of Toyama in Japan.
== Causes == SASP expression is induced by a number of transcription factors, including MLL1 (KMT2A), C/EBPβ, and NF-κB. NF-κB has been referred to as the master transcription factor controlling SASP expression. NF-κB and the enzyme CD38 are mutually activating. NF-κB is expressed as a result of inhibition of autophagy-mediated degradation of the transcription factor GATA4. GATA4 is activated by the DNA damage response factors, which induce cellular senescence. SASP is both a promoter of DNA damage response and a consequence of DNA damage response, in an autocrine and paracrine manner. Aberrant oncogenes, DNA damage, and oxidative stress induce mitogen-activated protein kinases, which are the upstream regulators of NF-κB. Demethylation of DNA packaging protein Histone H3 (H3K27me3) can lead to up-regulation of genes controlling SASP. mTOR (mammalian target of rapamycin) is also a key initiator of SASP. Interleukin 1 alpha (IL1A) is found on the surface of senescent cells, where it contributes to the production of SASP factors due to a positive feedback loop with NF-κB. Translation of mRNA for IL1A is highly dependent upon mTOR activity. mTOR activity increases levels of IL1A, mediated by MAPKAPK2. mTOR inhibition of ZFP36L1 prevents this protein from degrading transcripts of numerous components of SASP factors. Inhibition of mTOR supports autophagy, which can generate SASP components.
=== June === 1 June House prices in the UK are reported to have fallen by 3.4% in the year to May, the biggest decline since July 2009. The average property price is now estimated at £260,736. A ban on e-scooters carried on Southeastern, Southern, Thameslink and Gatwick Express trains comes into force, due to concerns over fire risk. 2 June – A visibly emotional Phillip Schofield gives an interview with the BBC's Amol Rajan, in which he apologises and says his "career is over" following the affair with a young male colleague. 3 June Train strikes staged by the ASLEF union cause disruption to the 2023 FA Cup final and a Beyoncé Knowles concert. In the FA Cup Final, the first in the 152-year history of the competition to feature a Manchester derby, Manchester City defeat rivals Manchester United 2–1 to win their seventh FA Cup trophy. A man is arrested at the FA Cup final after being pictured wearing a Manchester United shirt with the number 97 and the slogan "not enough", believed to be a reference to the Hillsborough disaster. The 33-year-old male is subsequently charged with displaying threatening or abusive writing likely to cause harassment, alarm or distress. A protestor is detained by police after attempting to disrupt the 2023 Epsom Derby by trespassing on the track. 6 June Record high numbers of gonorrhoea and syphilis infections are reported, following a dip during previous years.
Sources: en.wikipedia.org
=== Acute care and monitoring === Acute care and monitoring (ACM) is based out of Lafayette, Colorado and produces non-invasive sensors and monitoring products, used for patient monitoring in the hospital and home settings. It has absorbed the portfolios of acquired companies, including Covidien, Nellcor, Somanetics, Aspect Medical Systems, Oridion Medical and Zephyr Technology. This business unit produces pulse oximetry, capnography, and bispectral index sensors, patient monitors, remote patient monitoring software, and electronic medical record connectivity software.
=== Vaccine skepticism and connection to autism === In 2009, Carrey wrote an article questioning the merits of vaccination and discussing its connection to autism for The Huffington Post. With former partner Jenny McCarthy, Carrey led a "Green Our Vaccines" march in Washington, D.C., to advocate for the removal of "toxic substances" from children's vaccines, out of a belief that children had received "too many vaccines, too soon, many of which are toxic". The rally was criticized by David Gorski, an American surgical oncologist on Science-Based Medicine blog, for being anti-vaccine and not "pro-safe vaccine", and by Steven Parker on the WebMD website for being "irresponsible". In 2009, the couple appeared on Larry King Live to discuss autism. Carrey stated that he believes autism "is preventable and treatable," and that "it's still shocking to see how many people are ignoring this information." Carrey suggested rising autism rates was a warning about the medical industry, stating: "There's an autistic child on every block ... Autism is the canary in the coal mine. I believe that it's telling us that this vaccine program is imbalanced." On July 1, 2015, after the signing of a new vaccination law, Carrey called California governor Jerry Brown a "corporate fascist" who was "poisoning" children by enacting the vaccination requirements. The law disallowed religious and philosophical reasons for exemption from vaccination.
=== September === 1 September – Labour MP Jas Athwal sacks the letting agent managing his properties after a BBC investigation found they were infested with mould and ants. John Swinney gives his keynote speech to the SNP Annual Conference, saying that he will put the "people's priorities" at the heard of the Scottish Government, and that he will work to convince voters that Scottish independence is the "route" to delivering a fairer and stronger country. 2024 Social Democratic and Labour Party leadership election: Claire Hanna, the MP for Belfast South and Mid Down, confirms her intention to run as SDLP leader. 2 September – 2024 Conservative Party leadership election: Kemi Badenoch launches her leadership campaign with a speech in central London during which she says the Conservatives need to "stop acting like Labour". Former Labour Party leader Jeremy Corbyn unites with four other independent MPs to create the Independent Alliance, a pro-Gaza group and the joint fifth largest group in Parliament. 3 September – The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (England, Wales and Scotland) Order 2024 ceases to have effect. A leaked letter penned by Cabinet Secretary Simon Case describes the previous Conservative government's failure to hold a spending review in its final years in office as a contributing factor towards uncertainty over the state of public finances. Case also disputes the Conservative stance that Labour's allegation that they have inherited an economic "black hole" is bringing the civil service into disrepute.
=== Emissions from nuclear power plants === Carbon-14 is produced in coolant at boiling water reactors (BWRs) and pressurized water reactors (PWRs). It is typically released into the air in the form of carbon dioxide at BWRs, and methane at PWRs. Best practice for nuclear power plant operator management of carbon-14 includes releasing it at night, when plants are not photosynthesizing. Carbon-14 is also generated inside nuclear fuels (some due to transmutation of oxygen in the uranium oxide, but most significantly from transmutation of nitrogen-14 impurities), and if the spent fuel is sent to nuclear reprocessing then the 14C is released, for example as CO2 during PUREX.
AS9000 (1997) Aerospace Basic Quality System Standard As aerospace suppliers soon found that ISO 9001 (1994) did not address the specific requirements of their customers, including the DoD, NASA, FAA, and commercial aerospace companies including Boeing, Lockheed Martin, Northrop Grumman, GE Aircraft Engines and Pratt & Whitney, they developed AS9000, based on ISO 9001, to provide a specific quality management standard for the aerospace industry. Prior to the adoption of an aerospace specific quality standard, various corporations typically used ISO 9001 and their own complementary quality documentation/requirements, such as Boeing's D1-9000 or the automotive Q standard. This created a patchwork of competing requirements that were difficult to enforce and/or comply with. The major American aerospace manufacturers collaborated to develop a unified quality standard based on ISO 9001:1994, which led to the creation of AS9000. Following its release, companies like Boeing discontinued their previous quality supplements in favor of complying with AS9000.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.